Repligen Corporation Common Stock (RGEN)

FairStock Score: 36/100 — MIXED

Key Financials

Strengths

• Generates $76 million in annual free cash flow (1.2% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.33, providing financial flexibility
• Altman Z-Score of 5.2 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 18.1% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($27) with negative 314% margin of safety—limited downside protection

AI Analysis

Repligen Corporation Common Stock is a small-cap healthcare company valued at $6.3 billion. The business generates $738 million in annual revenue with a 1.8% net margin and $76 million in free cash flow. From a quality standpoint, Repligen shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 5.2 confirms fortress-level solvency. On valuation, the stock is commanding a steep 132.6x multiple, with trades far above its Graham Number ($27) with no margin of safety. Growth dynamics show revenue growing at 18.1% and profit growth of 139.2%. Our composite FairStock Score of 36/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Repligen's 18% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $76 million in annual free cash flow (1.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 133x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer